RET-IN-31
RET-IN-31 (Compound 13) is an orally active, selective RET inhibitor (IC50s: 1.4 nM, 1.9 nM, 3.8 nM for RETWT, RETV804L, RETV804M, respectively) . RET-IN-31 inhibits hERG and Cytochrome P450 (IC50s: 13.6 μM, 7.9 μM, 12.8 μM, 16.9 μM, 8.9 μM, 13.0 μM for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4-M, CYP3A4-T, respectively) . RET-IN-31 has anti-cancer effects against activated RET mutations and gene fusion-driven cancers[1].
Product Specifications
CAS Number
2491726-04-4
UNSPSC
12352005
Target
Cytochrome P450; Potassium Channel; RET
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
CC1=CC(NC2=CC(C)=NC(N3CC4N(C(C5=CN=C(N6N=CC(F)=C6)C=C5)=O)C(CC4)C3)=N2)=NN1
Molecular Formula
C24H25FN10O
Molecular Weight
488.52
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CYP1; CYP2; CYP3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-Human CD79α/CD79A Monoclonal Antibody (9H4), FITC
RFFL (RING Finger and FYVE-like Domain-containing Protein 1, E3 Ubiquitin-protein Ligase Rififylin, Caspase Regulator CARP2, Caspases-8 and -10-associated RING Finger Protein 2, CARP2, CARP-2, FYVE-RING Finger Protein Sakura, Fring, RING Finger Protein 189, RNF189, RING Finger Protein 34-like, RNF34L)